Abstract
LAG-3 (CD223) is a cell surface molecule expressed on activated T cells (Huard et al. Immunogenetics 39:213–217, 1994 ), NK cells (Triebel et al. J Exp Med 171:1393–1405, 1990 ), B cells (Kisielow et al. Eur J Immunol 35:2081–2088, 2005 ), and plasmacytoid dendritic cells (Workman et al. J Immunol 182:1885–1891, 2009 ) that plays an important but incompletely understood role in the function of these lymphocyte subsets. In addition, the interaction between LAG-3 and its major ligand, Class II MHC, is thought to play a role in modulating dendritic cell function (Andreae et al. J Immunol 168:3874–3880, 2002 ). Recent preclinical studies have documented a role for LAG-3 in CD8 T cell exhaustion (Blackburn et al. Nat Immunol 10:29–37, 2009 ), and blockade of the LAG-3/Class II interaction using a LAG-3 Ig fusion protein is being evaluated in a number of clinical trials in cancer patients. In this review, we will first discuss the basic structural and functional biology of LAG-3, followed by a review of preclinical and clinical data pertinent to a role for LAG-3 in cancer immunotherapy.

This publication has 45 references indexed in Scilit: